This brand name is authorized in Ireland, Poland, UK.
The drug ADDIPHOS contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
94255I6E2T - SODIUM PHOSPHATE, DIBASIC, DIHYDRATE
|
2
|
UNII
4J9FJ0HL51 - MONOBASIC POTASSIUM PHOSPHATE
|
|
Potassium is the principle cation in intracellular fluid. It is involved with carbohydrate metabolism, glycogen storage and protein synthesis. It is involved with transmembrane potential and profound effects on muscle. Phosphorus has many important biochemical functions in the body and is involved in many significant metabolic and enzyme reactions in almost all organs and tissues. |
|
3
|
UNII
WZH3C48M4T - POTASSIUM HYDROXIDE
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| B05XA30 | Combinations of electrolytes | B Blood and blood forming organs → B05 Blood substitutes and perfusion solutions → B05X I.V. solution additives → B05XA Electrolyte solutions |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| GB | Medicines & Healthcare Products Regulatory Agency | 137348, 52331 |
| PL | Rejestru Produktów Leczniczych | 100002817, 100342476, 100426977, 100455870, 100463081 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.